Our Mission. Qlibrium is committed to helping patients live life to the fullest by developing and innovating discreet and flexible drug delivery solutions. Our Aim. Qlibrium is developing a highly flexible platform technology for delivering injectable drugs into subcutaneous tissue with a wearable on-body delivery system that brings dramatic improvements over existing devices to both users and to pharmaceutical companies. Who is Qlibrium. Qlibrium, formerly known as Cam Med, began with a simple question: Why can’t a pump for injectable drugs work like an extension of the body? For patients with chronic conditions such as diabetes, Parkinson’s disease, hormone deficiencies, and blood disorders, as well as other conditions that require frequent injections of subcutaneous drugs, a better wearable pump translates into improved compliance and outcomes. Over the past several years, Qlibrium has been working to bring our vision of marked simplicity to reality with development of the QLib platform for prefilled delivery of drugs and biologics and QForma for diabetes patients. We have been issued several patents, with a strong portfolio of pending patents on key elements of our technology platform. We have been recognized with prizes from MassChallenge, the Centre for ADVANCEMENT OF SCIENCE IN SPACE, the New England Pediatric Device Consortium, the Massachusetts Medical Device Development Center, and we are a member of JLABS, part of Johnson & Johnson Innovation. Today, we are working with pharmaceutical partners to deliver a better experience to patients because patient acceptance builds compliance.